Market Newsdesk

March 31, 2025 4:09 pm

GDEV announces results for the fourth quarter and full year 2024

LIMASSOL, Cyprus, March 31, 2025 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), released its financial and operational results for the fourth quarter and full year ended December 31, 2024.

Fourth quarter 2024 financial highlights:

Revenue of $98 million declined by 12% quarter-over-quarter and 11% year-over-year.
Selling and marketing expenses of $47 million declined by 14% year-over-year driven by a shift in our user acquisition strategy to focus on higher margin audience.
We continue to adhere to our disciplined approach towards costs: game operation cost declined by 5% year-over-year, enhancing our operating margins.
Profit for the period, net of tax, of $2 million in Q4 2024 decreased vs. $11 million in Q4 2023, mostly due to the increase in finance expenses and share of loss of equity-accounted associates.
Adjusted EBITDA¹ of $12 million, representing a robust 22% increase year-over-year.
European market expansion strategy delivered exceptional results with regional bookings share growing by 5 percentage points to 32%, reflecting our successful targeted user acquisition campaigns and growing brand strength in the region.
Average Bookings Per Paying User (ABPPU) increased by 10% year-over-year to $102, highlighting improved monetization and the high quality of our engaged player base.
PC platform continued to strengthen our diversified distribution strategy, maintaining a solid 43% of bookings and supporting our lower commission structure.
Cash flows from operating activities remained positive at $5 million, supporting our strong cash position of $151² million and providing substantial resources for potential future strategic investments³.

Fourth quarter and full year 2024 financial performance in comparison
⁴

US$ million	Q4 2024		Q4⁵ 2023		Change (%)		FY⁶ 2024		FY 2023		Change (%)
Revenue	98		109		(11	%)	421		465		(9	%)
Platform commissions	(21	)	(25	)	(16	%)	(91	)	(109	)	(16	%)
Game operation cost	(13	)	(14	)	(5	%)	(51	)	(56	)	(9	%)
Selling and marketing expenses	(47	)	(54	)	(14	%)	(209	)	(226	)	(8	%)
General and administrative expenses	(8	)	(8	)	5	%	(32	)	(31	)	0	%
Profit for the period, net of tax	2		11		86	%	26		46		(45	%)
Adjusted EBITDA	12		10		22	%	42		43		(1	%)
Cash flows generated from operating activities	5		10		(51	%)	29		18		59	%

Fourth quarter 2024 financial performance

In the fourth quarter of 2024, our revenue declined 11% year-over-year to $98 million, reflecting a $12 million decrease. This decline was primarily driven by a $9 million reduction in revenue recognized from bookings made in prior periods, as a larger portion of historical bookings contributed to revenue in the fourth quarter of 2023 than in the fourth quarter of 2024, amplified by a decrease in the portion of revenue recognized from current-quarter bookings, reflecting a $12 million decrease in bookings in the fourth quarter of 2024 compared with the same period in 2023.

Platform commissions decreased by $4 million (or 16%) in the fourth quarter of 2024 compared to the same period in 2023, driven by a 10% decrease in revenues generated from in-game purchases, and amplified by growth of revenues derived from PC platforms which are associated with lower commissions.

Game operation cost remained relatively stable at the level of $13 million in the fourth quarter of 2024 vs. $14 million in the fourth quarter of 2023.

Selling and marketing expenses in the fourth quarter of 2024 decreased by $8 million vs. the same period in 2023, amounting to $47 million. The decrease is attributable to a shift in user acquisition strategy focused on enhancing efficiency.

General and administrative expenses remained stable at $8 million in both the fourth quarter of 2024 and the same period in 2023.

As a result of the factors above (together with, among other things, a share of loss of equity-accounted associates of $8 million in the fourth quarter of 2024 vs. nil in the same period in 2023, and net finance expenses in the fourth quarter of 2024 vs. net finance income in the same period in 2023 with a difference of $6 million), we recorded a profit for the period, net of tax, of $2 million compared with $11 million in the same period of 2024. Adjusted EBITDA in the fourth quarter of 2024 amounted to $12 million, an increase of $2 million compared with the same period in 2023.

Cash flows generated from operating activities were $5 million in the fourth quarter of 2024 compared with $10 million in the same period in 2023.

Fourth quarter and full year 2024 operational performance comparison

	Q4 2024		Q4 2023		Change (%)		FY 2024		FY 2023		Change (%)
Bookings ($ million)	94		106		(11	%)	404		422		(4	%)
Bookings from in-app purchases	89		99		(10	%)	377		391		(4	%)
Bookings from advertising	5		7		(20	%)	27		30		(11	%)
Share of advertising	5.8	%	6.5	%	(0.7 p.p.)		6.7	%	7.2	%	(0.5 p.p.)
MPU (thousand)	292		359		(19	%)	342		377		(9	%)
ABPPU ($)	102		92		10	%	92		86		6	%

Bookings declined in the fourth quarter of 2024 to reach $94 million compared with $106 million in the same period in 2023. The decline is primarily due to a decline in monthly paying users by 19% in the fourth quarter of 2024 vs. the same period in 2023, partially offset by an increase in ABPPU.

The share of advertisement sales as a percentage of total bookings decreased in the fourth quarter of 2024 to reach 5.8% compared to 6.5% in the same period in 2023. This decline was primarily driven by a global trend of declining CPM rates for advertising in 2024.

Split of bookings by platform	Q4 2024		Q4 2023		FY 2024		FY 2023
Mobile	57	%	57	%	60	%	62	%
PC	43	%	43	%	40	%	38	%

In the fourth quarter of 2024, the share of mobile and PC versions of our games remained relatively stable compared with the same period in 2023.

Split of bookings by geography	Q4 2024		Q4 2023		FY 2024		FY 2023
US	34	%	34	%	34	%	35	%
Asia	21	%	24	%	22	%	24	%
Europe	32	%	27	%	30	%	25	%
Other	13	%	15	%	14	%	16	%

Our split of bookings by geography in the fourth quarter of 2024 vs. the same period in 2023 remained broadly similar, with a notable increase in the share of Europe bookings.

Note:

Due to rounding, the numbers presented throughout this release may not precisely add up to the totals. The period-over-period percentage changes are based on the actual numbers and may therefore differ from the percentage changes if those were to be calculated based on the rounded numbers.

About GDEV

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Island Hoppers, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc

Contacts:

Investor Relations
Roman Safiyulin | Chief Corporate Development Officer
[email protected]

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2024 Annual Report on Form 20-F, filed by the Company on March 31, 2025, and other documents filed by the Company from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Presentation of Non-IFRS Financial Measures

In addition to the results provided in accordance with IFRS throughout this press release, the Company has provided the non-IFRS financial measure “Adjusted EBITDA” (the “Non-IFRS Financial Measure”). The Company defines Adjusted EBITDA as the profit/loss for the period, net of tax as presented in the Company’s financial statements in accordance with IFRS, adjusted to exclude (i) goodwill and investments in equity accounted associates’ impairment, (ii) loss on disposal of subsidiaries, (iii) income tax expense, (iv) other financial income, finance income and expenses other than foreign exchange gains and losses and bank charges, (v) change in fair value of share warrant obligations and other financial instruments, (vi) share of loss of equity-accounted associates, (vii) depreciation and amortization, (viii) share-based payments expense and (ix) certain non-cash or other special items that we do not consider indicative of our ongoing operating performance. The Company uses this Non-IFRS Financial Measure for business planning purposes and in measuring its performance relative to that of its competitors. The Company believes that this Non-IFRS Financial Measure is a useful financial metric to assess its operating performance from period-to-period by excluding certain items that the Company believes are not representative of its core business. This Non-IFRS Financial Measure is not intended to replace, and should not be considered superior to, the presentation of the Company’s financial results in accordance with IFRS. The use of the Non-IFRS Financial Measure terms may differ from similar measures reported by other companies and may not be comparable to other similarly titled measures.

Reconciliation of the profit for the period, net of tax to the Adjusted EBITDA

US$ million	Q4 2024		Q4 2023		FY 2024		FY 2023
Profit for the period, net of tax	2		11		26		46
Adjust for:
Income tax expense	1		1		5		4
Adjusted finance (income)/expenses⁷	0.7		(3	)	(2	)	(5	)
Change in fair value of share warrant obligations and other financial instruments	(0.6	)	(1	)	(0.9	)	(11	)
Share of loss of equity-accounted associates	8		0.5		8		0.5
Depreciation and amortization	2		2		6		6
Share-based payments	0.2		0.3		1		2
Adjusted EBITDA	12		10		42		43

^{_________________________________________}

¹ For more information, see section titled “Presentation of Non-IFRS Financial Measures” on the last two pages of this report, including the reconciliation of the profit for the period, net of tax to the Adjusted EBITDA.
² The amounts include investments in liquid high quality securities.
³ On February 21, 2025 the Company announced that its Board of Directors has authorized and approved a one-time, nonrecurring special cash dividend of $3.31 per share, representing an aggregate cash outflow of approximately $60 million.
⁴ For more information regarding our fully year 2024 financial performance, please see our 2024 Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 31, 2025.
⁵ The amounts presented for the three months and full year ended December 31, 2024 may be different to those previously reported for these periods, as starting from Q1 2024 the Company reports depreciation and amortization expenses by function as a part of game operation cost, selling and marketing expenses, and general and administrative expenses in accordance with IAS 1.
⁶ Certain numbers presented for the three months ended December 31, 2024 may not precisely add up with those previously reported for the nine months ended September 30, 2024, due to the correction of an error related to the reclassification of income from the write-off of a put option liability and the reclassification of certain amount between the impairment loss on trade and loan receivables and change in fair value of loans receivable and the share of loss of equity-accounted associates. As a result, the full-year 2024 figures presented herein reflect the corrected classification. Please refer to Note 33 of the Company’s consolidated financial statements, filed with the Securities and Exchange Commission on March 31, 2025.
⁷ Adjusted finance income/expenses consist of finance income and expenses other than foreign exchange gains and losses and bank charges, net.

March 31, 2025 4:04 pm

Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

Eaton Vance Closed-End Funds Release Estimated Sources of Distributions

BOSTON–(BUSINESS WIRE)–
The Eaton Vance closed-end funds listed below released today the estimated sources of their March distributions (each a “Fund”). This press release is issued as required by the Funds’ managed distribution plan (Plan) and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly, as noted below, cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the March distribution. It is not determinative of the tax character of a Fund’s distributions for the 2025 calendar year. Shareholders should note that each Fund’s total regular distribution amount is subject to change as a result of market conditions or other factors.

IMPORTANT DISCLOSURE: You should not draw any conclusions about each Fund’s investment performance from the amount of this distribution or from the terms of each Fund’s Plan. Each Fund estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all of the money that you invested in each Fund is paid back to you. A return of capital distribution does not necessarily reflect each Fund’s investment performance and should not be confused with “yield” or “income.” The amounts and sources of distributions reported in this notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for accounting and/or tax reporting purposes will depend upon each Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. Each Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

The following tables set forth estimates of the sources of each Fund’s March distribution and its cumulative distributions paid for its fiscal year through March 31, 2025, and information relating to each Fund’s performance based on its net asset value (NAV) for certain periods.

Eaton Vance Enhanced Equity Income Fund (NYSE: EOI)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.1338
Distribution Frequency:	Monthly
Fiscal Year End:	September
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0000	0.00%	$0.0000	0.00%
Net Realized Short-Term Capital Gains	$0.0000	0.00%	$0.0000	0.00%
Net Realized Long-Term Capital Gains	$0.1338	100.00%	$0.8028	100.00%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0000	0.00%
Total per common share	$0.1338	100.00%	$0.8028	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			15.49%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			7.96%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			2.82%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			3.32%

Eaton Vance Enhanced Equity Income Fund II (NYSE: EOS)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.1523
Distribution Frequency:	Monthly
Fiscal Year End:	December
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0000	0.00%	$0.0000	0.00%
Net Realized Short-Term Capital Gains	$0.0205	13.50%	$0.0206	4.50%
Net Realized Long-Term Capital Gains	$0.0832	54.60%	$0.1790	39.20%
Return of Capital or Other Capital Source(s)	$0.0486	31.90%	$0.2573	56.30%
Total per common share	$0.1523	100.00%	$0.4569	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			15.42%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			8.00%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			-0.64%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			1.33%

Eaton Vance Risk-Managed Diversified Equity Income Fund (NYSE: ETJ)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.0651
Distribution Frequency:	Monthly
Fiscal Year End:	December
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0000	0.00%	$0.0000	0.00%
Net Realized Short-Term Capital Gains	$0.0483	74.20%	$0.0483	24.70%
Net Realized Long-Term Capital Gains	$0.0168	25.80%	$0.1470	75.30%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0000	0.00%
Total per common share	$0.0651	100.00%	$0.1953	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			11.43%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			8.06%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			1.03%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			1.34%

Eaton Vance Tax-Advantaged Dividend Income Fund (NYSE: EVT)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.1646
Distribution Frequency:	Monthly
Fiscal Year End:	October
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0285	17.30%	$0.1338	16.30%
Net Realized Short-Term Capital Gains	$0.0387	23.50%	$0.0388	4.70%
Net Realized Long-Term Capital Gains	$0.0974	59.20%	$0.6504	79.00%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0000	0.00%
Total per common share	$0.1646	100.00%	$0.8230	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			11.59%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			7.48%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			3.19%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			2.49%

Eaton Vance Tax-Advantaged Global Dividend Opportunities Fund (NYSE: ETO)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.1733
Distribution Frequency:	Monthly
Fiscal Year End:	October
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0525	30.30%	$0.1118	12.90%
Net Realized Short-Term Capital Gains	$0.0000	0.00%	$0.0000	0.0%
Net Realized Long-Term Capital Gains	$0.1208	69.70%	$0.7547	87.10%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0000	0.00%
Total per common share	$0.1733	100.00%	$0.8665	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			12.62%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			7.42%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			3.79%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			2.47%

Eaton Vance Tax-Managed Buy-Write Income Fund (NYSE: ETB)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.1058
Distribution Frequency:	Monthly
Fiscal Year End:	December
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0045	4.30%	$0.0113	3.60%
Net Realized Short-Term Capital Gains	$0.0554	52.30%	$0.0554	17.40%
Net Realized Long-Term Capital Gains	$0.0459	43.40%	$0.2276	71.70%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0231	7.30%
Total per common share	$0.1058	100.00%	$0.3174	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			11.87%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			8.13%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			1.58%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			1.36%

Eaton Vance Tax-Managed Buy-Write Opportunities Fund (NYSE: ETV)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.0993
Distribution Frequency:	Monthly
Fiscal Year End:	December
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0020	2.00%	$0.0039	1.30%
Net Realized Short-Term Capital Gains	$0.0199	20.00%	$0.0841	28.20%
Net Realized Long-Term Capital Gains	$0.0774	78.00%	$0.2099	70.50%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0000	0.00%
Total per common share	$0.0993	100.00%	$0.2979	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			12.00%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			8.05%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			0.46%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			1.34%

Eaton Vance Tax-Managed Diversified Equity Income Fund (NYSE: ETY)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.0992
Distribution Frequency:	Monthly
Fiscal Year End:	October
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0000	0.00%	$0.0000	0.00%
Net Realized Short-Term Capital Gains	$0.0268	27.00%	$0.1224	24.70%
Net Realized Long-Term Capital Gains	$0.0724	73.00%	$0.3736	75.30%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0000	0.00%
Total per common share	$0.0992	100.0%	$0.4960	100.0%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			15.56%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			7.87%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			4.15%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			2.62%

Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund (NYSE: ETW)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.0664
Distribution Frequency:	Monthly
Fiscal Year End:	December
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0077	11.60%	$0.0189	9.50%
Net Realized Short-Term Capital Gains	$0.0000	0.00%	$0.0000	0.00%
Net Realized Long-Term Capital Gains	$0.0587	88.40%	$0.1392	69.90%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0411	20.60%
Total per common share	$0.0664	100.00%	$0.1992	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			9.43%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			8.49%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			2.55%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			1.41%

Eaton Vance Tax-Advantaged Global Dividend Income (NYSE: ETG)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.1293
Distribution Frequency:	Monthly
Fiscal Year End:	October
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0445	34.40%	$0.0694	10.70%
Net Realized Short-Term Capital Gains	$0.0000	0.00%	$0.0000	0.00%
Net Realized Long-Term Capital Gains	$0.0000	0.00%	$0.4410	68.20%
Return of Capital or Other Capital Source(s)	$0.0848	65.60%	$0.1361	21.10%
Total per common share	$0.1293	100.00%	$0.6465	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			12.55%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			7.50%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			3.68%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			2.50%

Eaton Vance Tax-Managed Global Diversified Equity Income Fund (NYSE: EXG)
Distribution Period:	March- 2025
Distribution Amount per Common Share:	$0.0657
Distribution Frequency:	Monthly
Fiscal Year End:	October
Source	Current Distribution	% of Current Distribution	Cumulative Distributions for the Fiscal Year- to-Date	% of the Cumulative Distributions for the Fiscal Year-to-Date
Net Investment Income	$0.0076	11.50%	$0.0189	5.80%
Net Realized Short-Term Capital Gains	$0.0459	70.00%	$0.0932	28.40%
Net Realized Long-Term Capital Gains	$0.0122	18.50%	$0.2164	65.80%
Return of Capital or Other Capital Source(s)	$0.0000	0.00%	$0.0000	0.00%
Total per common share	$0.0657	100.00%	$0.3285	100.00%

Average annual total return at NAV for the 5-year period ended on February 28, 2025 ¹			11.90%
Annualized current distribution rate expressed as a percentage of NAV as of February 28, 2025 ²			8.52%
Cumulative total return at NAV for the fiscal year through February 28, 2025 ³			3.71%
Cumulative fiscal year to date distribution rate as a percentage of NAV as of February 28, 2025 ⁴			2.84%



¹ Average annual total return at NAV represents the change in NAV of the Fund, with all distributions reinvested, for the 5-year period ended on February 28, 2025
² The annualized current distribution rate is the cumulative distribution rate annualized as a percentage of the Fund’s NAV as of February 28, 2025
³ Cumulative total return at NAV is the percentage change in the Fund’s NAV for the period from the beginning of its fiscal year to February 28, 2025 including distributions paid and assuming reinvestment of those distributions.
⁴ Cumulative fiscal year distribution rate for the period from the beginning of its fiscal year to February 28, 2025 measured on the dollar value of the distributions in year-to-date period as a percentage of the Fund’s NAV as of February 28, 2025

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331851375/en/

Investor Contact: (800) 262-1122

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

March 31, 2025 4:03 pm

Sterling Bancorp Announces Closing of Acquisition of Sterling Bank and Trust, F.S.B. by EverBank Financial Corp; Certificate of Dissolution to be Filed and Common Stock to be Delisted

Sterling Bancorp Announces Closing of Acquisition of Sterling Bank and Trust, F.S.B. by EverBank Financial Corp; Certificate of Dissolution to be Filed and Common Stock to be Delisted

SOUTHFIELD, Mich.–(BUSINESS WIRE)–
Sterling Bancorp, Inc. (NASDAQ: SBT) (“Sterling” or the “Company”), the holding company of Sterling Bank and Trust, F.S.B. (the “Bank”), today announced the closing of the previously announced sale of all of the issued and outstanding shares of capital stock of the Bank to EverBank Financial Corp, a Delaware corporation (“EverBank”), which will become effective as of 12:01 a.m. (Eastern Time) on April 1, 2025. In connection with the closing of the sale, the Company received a fixed purchase price of $261 million in cash pursuant to the definitive Stock Purchase Agreement by and among the Company, the Bank and EverBank, dated September 15, 2024. Additionally, immediately following the effectiveness of the sale transaction, the Bank will be merged with and into EverBank, National Association, the bank subsidiary of EverBank, with EverBank, National Association as the surviving bank. Following the effectiveness of the bank merger, the separate corporate existence of the Bank will cease. All branches of the Bank, other than its Michigan branch, will open as EverBank branches on April 1, 2025. Former Sterling customers at those branches will receive additional information regarding the effects of the bank merger on their deposit and loan accounts. The Bank’s Michigan branch has been closed, effective as of the close of business on March 31, 2025.

The Company also today announced that, consistent with the Plan of Dissolution, the Company expects to file a certificate of dissolution with the Michigan Department of Licensing and Regulatory Affairs on April 1, 2025 in order to wind down and dissolve the Company in accordance with Michigan law. Once the certificate of dissolution is filed, the Company will close its stock transfer books. In addition, the Company will request that its common stock be delisted from the Nasdaq Capital Market and has requested that trading in the common stock be suspended as of the close of business today.

Effective as of the closing of the sale transaction, Peggy Daitch, Tracey Dedrick, Benjamin Wineman and Eboh Okorie have resigned from their roles as directors of the Company.

“The closing of this transaction with EverBank was only possible with the extraordinary contributions of our Board of Directors, Executive team, and all Sterling employees. We were also fortunate to have had the opportunity to work with the EverBank team to complete this transaction. They have been an excellent and cooperative partner during this transition period and I am convinced that they will enjoy a successful future with the Sterling staff and branch locations that are added to theirs. This sale marks the closing of an almost five-year tenure at Sterling for me. The opportunity to turn the Bank around from its difficulties has been an experience that I will not forget. The pleasure of working with so many talented bankers has made the workload manageable and the outcome successful. I am also thankful to our shareholders for the consistent support, patience and encouragement shown to me throughout my term of office, and as we commence the wind down process for Sterling Bancorp. I expect we will communicate with you in the next day or so on the dissolution, wind down and initial liquidating distribution,” said Thomas M. O’Brien, Chairman, President and Chief Executive Officer.

About Sterling Bancorp, Inc.

Prior to completion of the sale, Sterling Bancorp, Inc. is a unitary thrift holding company. Its wholly owned subsidiary, Sterling Bank and Trust, F.S.B., has primary branch operations in the San Francisco and Los Angeles, California metropolitan areas and New York City. Sterling offers a range of loan products as well as retail and business banking services. Sterling also has an operations center and a branch in Southfield, Michigan. For additional information, please visit the Company’s website at https://investors.sterlingbank.com.

Forward-Looking Statements

This Press Release contains certain statements that are, or may be deemed to be, “forward-looking statements” regarding the Company’s plans, expectations, thoughts, beliefs, estimates, goals and outlook for the future. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance, including any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions. These statements are often, but not always, made through the use of words or phrases such as “may,” “might,” “should,” “could,” “believe,” “expect,” “continue,” “will,” “estimate,” “intend,” “plan,” “anticipate,” and “would” or the negative versions of those words or other comparable words or phrases of a future or forward-looking nature, though the absence of these words does not mean a statement is not forward-looking. All statements other than statements of historical facts, including but not limited to statements regarding the economy and financial markets, threatened litigation, credit quality, the regulatory scheme governing our industry, competition in our industry, interest rates, our liquidity, our business and our governance, are forward-looking statements. We have based the forward-looking statements in this Press Release primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy and financial needs. These forward-looking statements are not historical facts, and they are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. There can be no assurance that future developments will be those that have been anticipated. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. The risks, uncertainties and other factors detailed from time to time in our public filings, including those included in the disclosures under the headings “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 14, 2025, subsequent periodic reports and future periodic reports, could affect future results and events, causing those results and events to differ materially from those views expressed or implied in the Company’s forward-looking statements. These risks are not exhaustive. Other sections of this Press Release and our filings with the Securities and Exchange Commission include additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Press Release. Should one or more of the foregoing risks materialize, or should underlying assumptions prove incorrect, actual results or outcomes may vary materially from those projected in, or implied by, such forward-looking statements. Accordingly, you should not place undue reliance on any such forward-looking statements. The Company disclaims any obligation to update, revise, or correct any forward-looking statements based on the occurrence of future events, the receipt of new information or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331443514/en/

Investor Contact:

Sterling Bancorp, Inc.

Karen Knott

Executive Vice President and Chief Financial Officer

(248) 359-6624

[email protected]

KEYWORDS: United States North America California Michigan

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

March 31, 2025 3:56 pm

TIXT Deadline: TIXT Investors Have Opportunity to Lead TELUS International (Cda) Inc. Securities Fraud Lawsuit

PR Newswire

NEW YORK
, March 31, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TELUS International (Cda) Inc. (NYSE: TIXT) between February 16, 2023 and August 1, 2024, both dates inclusive (the “Class Period”), of the important March 31, 2025 lead plaintiff deadline.

So what: If you purchased TELUS International securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the TELUS International class action, go to https://rosenlegal.com/submit-form/?case_id=34482 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 31, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants, throughout the Class Period, failed to disclose to investors that: (1) TELUS International’s AI Data Solutions offerings required the cannibalization of its higher-margin offerings; (2) TELUS International’s declining profitability was tied to TELUS International’s drive to develop AI capabilities; (3) TELUS International’s shift toward AI put greater pressure on the company’s margins than previously disclosed; and (4) as a result of the foregoing, defendants’ positive statements about TELUS International’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TELUS International class action, go to https://rosenlegal.com/submit-form/?case_id=34482 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tixt-deadline-tixt-investors-have-opportunity-to-lead-telus-international-cda-inc-securities-fraud-lawsuit-302415955.html

SOURCE THE ROSEN LAW FIRM, P. A.

March 31, 2025 3:52 pm

NEM Deadline: NEM Investors Have Opportunity to Lead Newmont Corporation Securities Fraud Lawsuit

PR Newswire

NEW YORK
, March 31, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Newmont Corporation (NYSE: NEM) between February 22, 2024 and October 23, 2024, inclusive (the “Class Period”), of the important April 1, 2025 lead plaintiff deadline.

So what: If you purchased Newmont securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Newmont class action, go to https://rosenlegal.com/submit-form/?case_id=34541 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 1, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, during the Class Period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning Newmont’s ability to deliver increased gold production at its Tier 1 operations, specifically, Lihir and Brucejack, in addition to lowering overall costs throughout its mining operations. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Newmont class action, go to https://rosenlegal.com/submit-form/?case_id=34541 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nem-deadline-nem-investors-have-opportunity-to-lead-newmont-corporation-securities-fraud-lawsuit-302415940.html

SOURCE THE ROSEN LAW FIRM, P. A.

March 31, 2025 3:51 pm

GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit

PR Newswire

NEW YORK
, March 31, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important May 12, 2025 lead plaintiff deadline.

So what: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Geron class action, go to https://rosenlegal.com/submit-form/?case_id=36747 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 12, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) despite contrary representations to investors, a lack of awareness of RYTELO among health care providers, the weekly monitoring requirement, and seasonality and existing competition would impair Geron’s ability to capitalize on the purportedly significant unmet need for the drug; (2) accordingly, the RYTELO launch was unlikely to be as profitable as Geron had led investors to believe; (3) as a result, Geron’s business and/or financial prospects were overstated; and (4) as a result, Geron’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Geron class action, go to https://rosenlegal.com/submit-form/?case_id=36747 or https://rosenlegal.com/submit-form/?case_id=28116call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

View original content to download multimedia:https://www.prnewswire.com/news-releases/gern-investors-have-opportunity-to-lead-geron-corporation-securities-fraud-lawsuit-302415945.html

SOURCE THE ROSEN LAW FIRM, P. A.

March 31, 2025 3:49 pm

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron^® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial –

– Halneuron^® CINP P2b study interim data readout is expected in Q4 2025 –

– Conversion of existing $19.5M in debt to equity, strengthens balance sheet moving forward –

– Capital raise provides operational runway through Q1 2026 –

ATLANTA, March 31, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announced financial results for the fourth quarter and full year ended December 31, 2024.

“We have made considerable progress in advancing our flagship Halneuron^® CINP Phase 2b study, with interim data expected by year end. We have also significantly improved our balance sheet and liquidity over the past few months, improving our cash position in a recent capital raise along with the agreement of our largest shareholder to exchange all their outstanding loan amounts for equity,” said Greg Duncan, Chief Executive Officer of Dogwood Therapeutics. “We believe this substantial organizational progress, in the context of future milestones, positions Dogwood as a more attractive investment opportunity moving forward.”

Key Highlights

The Company commenced dosing in its Halneuron^® Phase 2b CINP program this month, with potential to be the first FDA approved therapy for the treatment of CINP.
Based on its conviction in Halneuron^® and the Dogwood Therapeutics management team’s ability to execute, the Company’s largest shareholder, CK Life Sciences (Holdings) Int’l, converted through an affiliate their outstanding $19.5 million loan to equity, improving the Company’s balance sheet.
Recent $4.8 million common stock capital raise, combined with existing cash, provides the Company with operational runway through the first quarter of 2026.

Dogwood Therapeutics Proprietary Pipeline Includes:

Halneuron
^® is in Phase 2b development as a non-opioid, Na_V 1.7 inhibitor to treat the neuropathic pain associated with chemotherapy treatment. Halneuron^® has been granted fast track designation from the Food and Drug Administration (“FDA”) for the treatment of CINP.

Next milestone: Interim data from the ongoing Phase 2b CINP study are expected in Q4 2025.

IMC-2 (valacyclovir + celecoxib) is in Phase 2a development as a combination antiviral treatment for Long-COVID.

Next milestone: Dogwood is simultaneously exploring external funding and/or a partnership to advance IMC-2 into Phase 2b development as a treatment for Long-COVID.

IMC-1 (famciclovir + celecoxib) is ready for Phase 3 development as a combination antiviral treatment for Fibromyalgia (“FM”). IMC-1 has been granted fast track designation by the FDA for the treatment of FM.

Next milestone: Dogwood is exploring partnerships for IMC-1 to execute the Phase 3 FM program agreed upon by the FDA and will provide an update in Q2 of this year.

Fourth Quarter 2024 Financial Results

Research and development expenses for the fourth quarter of 2024 were $2.3 million, compared to $0.3 million for the fourth quarter of 2023. The $2.0 million increase quarter over quarter was due to increases in expenses for clinical trials of $1.1 million, drug development and manufacturing costs of $0.6 million and salaries and related personnel costs of $0.3 million.

General and administrative expenses for the fourth quarter of 2024 were $5.2 million, compared to $0.8 million for the fourth quarter of 2023. The $4.4 million increase quarter over quarter was primarily due to nonrecurring transaction costs of $3.9 million related to the combination of Pharmagesic in October 2024 and an increase in salaries and related personnel costs of $0.5 million.

Net loss attributable to common stockholders for the fourth quarter of 2024 was $8.2 million, or $6.29 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $1.1 million, or $1.43 basic and diluted net loss per share, for the fourth quarter of 2023.

Full Year 2024 Financial Results

Research and development expenses for the year ended December 31, 2024 were $3.5 million, compared to $1.7 million for the year ended December 31, 2023. The $1.8 million increase was primarily due to increases in expenses for clinical trials of $1.0 million, research and preclinical activities of $0.3 million, drug development and manufacturing costs of $0.4 million, and salaries and related personnel costs of $0.3 million partially offset by a decrease in regulatory consulting of $0.2 million.

General and administrative expenses for the year ended December 31, 2024 were $8.7 million, compared to $3.7 million for the year ended December 31, 2023. The $5.0 million increase was primarily due to nonrecurring transaction costs of $4.9 million related to the combination of Pharmagesic in October 2024, an increase in salaries and related personnel costs of $0.4 million partially offset by a decrease of $0.3 million related to insurance costs associated with being a public company.

Net loss attributable to common stockholders for the year ended December 31, 2024 was $12.9 million, or $12.52 basic and diluted net loss per share, compared to a net loss attributable to common stockholders of $5.3 million, or $7.05 basic and diluted net loss per share, for the year ended December 31, 2023.

As of December 31, 2024, Dogwood Therapeutics’ cash totaled $14.8 million. The Company believes it has sufficient resources to fund operations through the first quarter of 2026.

About Dogwood Therapeutics

Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Na_V 1.7 analgesic program is centered on our lead development candidate, Halneuron^®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron^® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). Interim data from the ongoing Halneuron^® Phase 2 CINP study are expected in Q4 of 2025.

Dogwood’s antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.

For more information, please visit www.dwtx.com.

Forward-Looking Statements:

Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

Investor Relations:

CORE IR
(516) 222-2560
[email protected]

-Financial Tables Follow-

DOGWOOD THERAPEUTICS

Selected Financial Data
(unaudited)


Condensed Consolidated	Three Months Ended						Year Ended
Statements of Operations Data	December 31,						December 31,
	2024			2023			2024			2023
Revenue	$	—		$	—		$	—		$	—
Operating expenses:
Research and development		2,315,950			298,320			3,530,913			1,728,078
General and administrative		5,226,202			839,806			8,696,335			3,718,841
Total operating expenses		7,542,152			1,138,126			12,227,248			5,446,919
Loss from operations		(7,542,152	)		(1,138,126	)		(12,227,248	)		(5,446,919	)
Other (expense) income:
Interest (expense) income, net		(155,436	)		34,953			(92,192	)		150,904
Exchange loss, net		(30,787	)		—			(30,787	)		—
Total other (expense) income, net		(186,223	)		34,953			(122,979	)		150,904
Loss before income taxes		(7,728,375	)		(1,103,173	)		(12,350,227	)		(5,296,015	)
Deferred income tax provision		503			—			503			—
Net Loss		(7,727,872	)		(1,103,173	)		(12,349,724	)		(5,296,015	)
Accrual of paid-in-kind dividends on
Series A non-voting convertible
preferred stock		(514,105	)		—			(514,105	)		—
Net loss attributable to common
stockholders	$	(8,241,977	)	$	(1,103,173	)	$	(12,863,829	)	$	(5,296,015	)
Net loss per share of common stock —
basic and diluted, as adjusted	$	(6.29	)	$	(1.43	)	$	(12.52	)	$	(7.05	)
Weighted average shares outstanding
— basic and diluted, as adjusted		1,310,474			770,317			1,027,788			751,071

Condensed Consolidated Balance Sheet Data	December 31,			December 31,
	2024			2023

Cash	$	14,847,949		$	3,316,946
Total assets		94,308,246			4,165,442
Total liabilities		30,027,223			358,548
Total stockholders’ (deficit) equity		(10,124,339	)		3,806,894

Source: Dogwood Therapeutics, Inc.

March 31, 2025 3:03 pm

Five New Must-Try Items from Kroger Our Brands Lineup

PR Newswire

Retailer on-track to launch more than 900 new items in 2025

CINCINNATI
, March 31, 2025 /PRNewswire/ — The Kroger Co. (NYSE: KR), America’s grocer, today shared it is introducing new Our Brands products, sharing five must try items hitting Kroger shelves. Customers can look forward to unique new products from Kroger®, Private Selection® and Simple Truth®, bringing Our Brands’ signature quality and affordability to more grocery staples.

“Kroger Our Brands’ unmatched flavor and value make them a favorite for many customers,” said Mike Murphy, Kroger’s group vice president of center store merchandising. “Our product innovation is rooted in a deep understanding of what our customers want and need. We know these exciting, trendy items will soon earn a place on families’ dinner tables because they offer great flavors at a price point that fits any budget.”

Check out these top five new Our Brands must try items:

Private Selection
®
Salad Kits
Elevate a quick lunch, make an easy side dish and enjoy everything in between with six new Private Selection salad kits. These kits feature a variety of fresh, high-quality ingredients, including crisp greens, vibrant vegetables and flavorful dressings, all prepped and ready to toss together.

The new lineup includes classic favorites paired with one-of-a-kind flavors. Try the Cheddar Truffle, Blueberry, Cheddar Bacon Poblano, Sweet Onion Gruyere, Cherry Bacon Cheddar and Asian Sesame Ginger.

Kroger® Brand Kettle Style Tortilla Chips
Kroger’s Tortilla Chips have long been a staple for many customers, and now there is a new variety to love with the introduction of Kroger® Brand Kettle Style Cooked Tortilla Chips. Available in two varieties—Traditional and Hatch Chile, these chips offer a robust and crunchy texture, making them the ultimate companion for dips and salsas.

Kroger
® Brand Restaurant Style Italian Dressing
Enjoy high quality salads and meals at home with Kroger’s new Restaurant Style Italian Dressing. Crafted with Italian spices, oil, vinegar and real Romano cheese, this dressing can transform a salad or vegetables and even be used as a marinade in a favorite recipe.

Simple Truth Organic
®
Instant Mushroom Tea
After rave reviews for Simple Truth Organic® Mushroom Instant Coffee, customers can now enjoy Simple Truth Organic® Instant Mushroom Tea available in two blends—Black and Chai.

This innovative tea blend harnesses mushrooms’ natural benefits, known for their adaptogenic properties and potential to support wellness. With its rich, earthy flavor profile, Mushroom Tea is perfect for those looking to explore a new beverage.

Private Selection
®
Muffins
Sweeten the morning routine with new Private Selection® Muffins, a gourmet option available in four flavors—Banana Bread, Blueberry Lemon, Coffee Cake and Triple Chocolate. These muffins range from rich and decadent to fruity and refreshing, with the perfect amount of sweetness.

To shop all the new arrivals and fresh finds, visit Kroger.com or the Kroger app, offering more than $600 in savings available weekly in digital coupons. With more than 30,000 mouthwatering possibilities, customers are a swipe away from inspiration to reality. Kroger is worth it every time.

Customers can shop fresh ingredients and more in-store or through Kroger Pickup and Delivery offering the same fresh products at the same low prices no matter how they shop. Save even more with Boost by Kroger Plus, the delivery membership that can save customers up to $1,100* per year on fuel, exclusive savings, streaming options** and grocery delivery.

* Savings for Boost $99 membership, based on 2 deliveries per week, $91 weekly grocery spend, 13 gallons per fill-up and Fuel Point redemption twice per month. Along with streaming value of $119 based on $9.99 monthly fee for Disney+ Basic (With Ads) and Hulu (With Ads), and $11.99 monthly fee for ESPN+.

** Eligible subs only. Restrictions Apply. See retailer site for details.

About Kroger
At The Kroger Co. (NYSE: KR), we are dedicated to our Purpose: To Feed the Human Spirit™. We are, across our family of companies nearly 420,000 associates who serve over 11 million customers daily through a seamless digital shopping experience and retail food stores under a variety of banner names, serving America through food inspiration and uplift, and creating #ZeroHungerZeroWaste communities. To learn more about us, visit our newsroom and investor relations site.

View original content to download multimedia:https://www.prnewswire.com/news-releases/five-new-must-try-items-from-kroger-our-brands-lineup-302416041.html

SOURCE The Kroger Co.

March 31, 2025 3:03 pm

Alamos Gold Provides Notice of Completion of Annual Filings

All amounts are in United States dollars, unless otherwise stated.

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today announced that it has filed its annual information form and 2024 annual report on Form 40-F, including its audited financial statements for the year ended December 31, 2024, with the SEC on EDGAR as well as the Canadian securities authorities on SEDAR+. These documents are also available at www.alamosgold.com and a hard copy will be provided to shareholders free-of-charge upon request.

About Alamos

Alamos is a Canadian-based intermediate gold producer with diversified production from three operations in North America. This includes the Island Gold District and Young-Davidson mine in northern Ontario, Canada, and the Mulatos District in Sonora State, Mexico. Additionally, the Company has a strong portfolio of growth projects, including the Phase 3+ Expansion at Island Gold, and the Lynn Lake project in Manitoba, Canada. Alamos employs more than 2,400 people and is committed to the highest standards of sustainable development. The Company’s shares are traded on the TSX and NYSE under the symbol “AGI”.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Scott K. Parsons
Senior Vice President, Corporate Development & Investor Relations
(416) 368-9932 x 5439

Khalid Elhaj

Vice President, Business Development & Investor Relations
(416) 368-9932 x 5427
[email protected]

The TSX and NYSE have not reviewed and do not accept responsibility for the adequacy or accuracy of this release.

March 31, 2025 2:09 pm

Newton Golf Company to Host Fourth Quarter and Full-Year 2024 Earnings Call on March 31, 2025

CAMARILLO, Calif., March 31, 2025 (GLOBE NEWSWIRE) — via IBN – Newton Golf Company (Nasdaq: NWTG), a developer of performance-focused golf equipment, today announced it will host an earnings call to discuss its fourth quarter and full-year 2024 financial results on Monday, March 31, 2025 at 4:30PM ET.

Earnings Call Details

• Date: March 31, 2025
• Time: 4:30 PM ET
• Participant Listening Options:
Participant Listening: 1-877-407-0779 or 1 201-389-0914

Callme™: https://callme.viavid.com/viavid/?callme=true&passcode=13752919&h=true&info=company&r=true&B=6

– Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.
– Call me™ link will be made active 15 minutes prior to scheduled start time.

The call will feature remarks from Greg Campbell, Chairman and CEO, providing an overview of the Company’s financial performance and strategic outlook.

A recording of the call will be available following the event via the Investor Relations section of the Company’s website at www.newtongolfir.com.

‍Investor Alerts

Stay updated with the latest from Newton Golf! Investors and stakeholders can sign up for email alerts at newtongolfir.com/email-alerts to receive company news, updates, and strategic developments directly in their inbox.

For more information, visit Newtongolfir.com.

About Newton Golf

At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or the future financial performance of Newton Golf Company (the “Company”) and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “believes,” “estimates,” “projects,” “potential,” “continues,” or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the reverse stock split, the Company’s ability to maintain compliance with Nasdaq listing requirements, the potential for increased institutional investor interest, the Company’s future growth strategy, expansion of its product portfolio, anticipated financial performance, and future business prospects.

These forward-looking statements reflect the Company’s current expectations and projections based on information available as of the date of this release and are subject to a number of risks and uncertainties, including, but not limited to, general economic, financial, and business conditions; changes in consumer demand and industry trends; the Company’s ability to successfully implement its strategic initiatives; competition in the golf equipment market; supply chain disruptions; regulatory compliance and legal proceedings; and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission (SEC), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q.

The Company cautions investors that forward-looking statements are not guarantees of future performance and actual results may differ materially from those projected. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Company Contact:
Newton Golf Company
551 Calle San Pablo
Camarillo, CA 93012
https://newtongolfco.com/

Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
[email protected]